Review
Copyright ©The Author(s) 2021.
World J Gastroenterol. Jul 21, 2021; 27(27): 4322-4341
Published online Jul 21, 2021. doi: 10.3748/wjg.v27.i27.4322
Table 6 Studies evaluating percutaneous liver ablation in metastatic pancreatic cancer
Ref.
Modality
Patients
Median OS from ablation
Guidance
Major adverse events
Park et al[77], 2012RFA3414 moUSNot reported
Hua et al[78], 2017RFA10211.4 moUS9.8%
Lee et al[79], 2020RFA9412 moUS (n = 91), CT (n = 3)8.5%
Bailey et al[80], 2019Mixed209.7 moMixedN/A